Global Dengue Vaccine Market Forecast 2016-2024: Market to Grow At A CAGR Of 17% And Reach USD 1.15 Billion

Government Institutes dominate the global dengue vaccine market, accounting 45% market share in 2017 and is expected to account for 52% global dengue vaccine market share by 2024 followed by hospitals, diagnostic labs and NGO’s.

According to WHO, number of deaths caused by dengue virus was 297, 873 in 2012 and 159 per million in low income, lower-middle income and upper-middle income regions. The global market for dengue vaccines holds the opportunities for drugmakers when the will be able to successfully develop effective vaccines for all age group. The major growth driver of global dengue vaccine market is the process of urbanization. Due to lack of specific therapeutics and prevention in dengue which is currently limited to vector control measures. Buildout tetravalent dengue vaccine is considered as a high public health priority.  ICGEB is partnering with Sun Pharma for research and development of an injectable vaccine that prevents against all four dengue strains that are endemic to India.

According to Goldstein Research, the global dengue vaccine market is segmented based on technology and end user. Technology segment is further sub-segmented into live attenuated vaccine, chimeric live attenuated vaccine, subunit vaccine, inactivated vaccine and nucleic acid based vaccine. Brazil and Mexico are anticipated to be leading contributors to the dengue vaccine market, estimated to be around USD 0.08 billion in 2016 to USD 0.5 billion by 2024 and grow at a compound annual growth rate (CAGR) of 40% followed by India, Singapore and Thailand while more than 70% of global dengue vaccine revenue was emanated from APAC in 2016.

“Global Dengue Vaccine Market Outlook, 2016-2024” covers the present ground scenario and future opportunity prospects for the market players to analyze the target markets across the globe. Moreover, competitive analysis includes the in-depth analysis of the major players and leaders in healthcare industry. The market study conducted on the basis of primary as well as secondary research where the analysts fragment the data from various databases such as Bloomberg, Factiva, Owler and others. Our primary research team conducted various interviews, surveys and group discussions of industry dengue vaccine manufacturers, suppliers, and distributors, pharmaceutical & biotechnology companies, healthcare institutions, clinical centers, medical research laboratories and academic medical centers and universities to analyze the future prospects of the overall healthcare industry.

Global Dengue Vaccine Market Segmentation can be classified on the basis of:

By Technology

  • Live attenuated vaccine
  • Chimeric Live attenuated vaccine
  • Subunit vaccine
  • Inactivated vaccine
  • Nucleic acid based vaccine

By End Users

  • Hospital
  • Diagnostic Labs
  • NGO’s
  • Government Institutes
  • Others (retail pharmacies, online pharmacies, etc)

By Geography

  • North America (US, Canada) Dengue Vaccine Market {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
  • Europe (UK, France, Italy, Germany, Spain, Hungary, Sweden, Russia, Poland and Rest of Europe) Dengue Vaccine Market {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
  • Middle East and Africa (GCC Countries, North Africa, South Africa and Rest of Middle East & Africa) Dengue Vaccine Market {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
  • Latin America (Brazil, Mexico and Rest of Latin America) Dengue Vaccine Market {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}
  • Asia Pacific (China, Japan, India, Singapore, South Korea, Australia, New Zealand and Rest of Asia-Pacific) Dengue Vaccine Market {Market Share (%), Market Size (USD Billion), Adoption Rate (%)}

Market Trends, Drivers and Challenges

Merger & acquisition is the key strategy for the vendors of dengue market, for instance, Sanofi “Be a Wall against Dengue” disease education campaign to raise awareness on dengue prevention in Singapore, launched under partnership of Pasteur and Ya Kun Kaya Toast in conjunction with ASEAN Dengue Day (15 June 2017). Similarly, Takeda pharmaceutical company and Biological E. limited entered into a partnership for the development and delivery of low-cost combination vaccines. There are 5 vaccines in Phase I-III and 4 first-in-class vaccines in pipeline assessment. The key driving factors of global dengue market are increasing dengue fever occurrence, promising end stage vaccine pipeline, local production of dengue vaccines and innovation of live attenuated tetravalent dengue vaccine. Unplanned and uncontrolled urbanization, stiff competition among existing players, high possibilities of side effects, lack of basic amenities in communities, poor environmental management, and climatic change hinders the global dengue vaccine market.

Global Dengue Vaccine Market Report” has been prepared based on an in-depth market analysis from industry experts. The report covers the competitive landscape and current position of major players in the market space. The report also includes porter’s five force model, SWOT analysis, company profiling, business strategies of market players and their business models. Global Dengue Vaccine market report also recognizes value chain analysis to understand the cost differentiation to provide competitive advantage to the existing and new entry players.

Request Report Sample @ https://www.goldsteinresearch.com/request-sample/global-dengue-vaccine-market-outlook-2024-global-opportunity-and-demand-analysis-market-forecast-2016-2024

About Goldstein Research

Based in U.S., Goldstein Research is a young business consulting and market research firm with vast reach across America, Asia and parts of Europe and the Middle East.  In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions. With 30+ domain experts and 50+ employees working day and night to crunch numbers and bring out the best and detailed market reports and forecasts, we strive to enable you to foresee upcoming market challenges and develop a robust business model and strategies, which would add to your profitability and market visibility as a brand.

Media Contact
Company Name: Goldstein Research
Contact Person: Steve blade
Email: stevebladeusa@gmail.com
Phone: +1-6465687747
Address:99 Wall Street, Suite No:- 527
City: New York,
State: NY
Country: United States
Website: http://www.goldsteinresearch.com/